Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash from Investing Activities (2020 - 2022)

Guided Therapeutics' Cash from Investing Activities history spans 8 years, with the latest figure at -$3000.0 for Q4 2022.

  • For Q4 2022, Cash from Investing Activities rose 25.0% year-over-year to -$3000.0; the TTM value through Mar 2023 reached -$21000.0, up 22.22%, while the annual FY2022 figure was -$31000.0, 121.43% down from the prior year.
  • Cash from Investing Activities for Q4 2022 was -$3000.0 at Guided Therapeutics, up from -$14000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$1000.0 in Q3 2020 and bottomed at -$14000.0 in Q1 2022.
  • The 3-year median for Cash from Investing Activities is -$4000.0 (2021), against an average of -$4571.4.
  • The largest YoY upside for Cash from Investing Activities was 25.0% in 2022 against a maximum downside of 1300.0% in 2022.
  • A 3-year view of Cash from Investing Activities shows it stood at -$1000.0 in 2020, then plummeted by 300.0% to -$4000.0 in 2021, then increased by 25.0% to -$3000.0 in 2022.
  • Per Business Quant, the three most recent readings for GTHP's Cash from Investing Activities are -$3000.0 (Q4 2022), -$14000.0 (Q1 2022), and -$4000.0 (Q4 2021).